ALPHA — Pharnext SCA Share News
0.000.00%
Last trade - 00:00HealthcareHighly SpeculativeMicro Cap
Brief: Pharnext H1 Operating Loss Narrows To 7.8 Million Euros
Brief: Pharnext And Charcot-Marie-Tooth Association Announce Biomarker Research Collaboration
Brief: Pharnext To Begin Last PXT3003 Phase III Study Before End Q1-21
Brief: Pharnext FY Net Loss Widens To 23.3 Million Euros
Brief: Pharnext Announces Partnership To Evaluate Drugs For Potential Use Against COVID-19
Brief: Pharnext Identifies Frequently Prescribed Drugs To Be Repurposed For Fighting Covid-19
Brief: Pharnext Says PXT3003 For Treatment Of Charcot-Marie-Tooth Disease Type 1A Granted PIM Designation
Brief: Pharnext Announces Capital Increase Of Around 7.7 Million Euros
Brief: Pharnext Announces Data From Open-Label Phase 3 Extension Study Of PXT3003
Brief: Pharnext Establishes Equity Line Facility With Kepler Cheuvreux
Brief: Pharnext H1 Net Loss Widens At 12.3 Millions Euros
Brief: Pharnext Updates On Collaboration with Galapagos
Brief: Pharnext Says FDA Recommends To Conduct Additional Phase 3 Study To Evaluate PXT3003
Brief: Pharnext Announces Apppointment Of Peter Collum As CFO And Chief Business Officer
Brief: Pharnext FY Net Loss Widens To 21.3 Million Euros
Brief: Pharnext Announces Reinforcement Of Equity Capital By Conversion Of Convertible Bonds
Brief: Pharnext Announces FDA Fast Track Designation For PLEODRUG(TM) PXT3003
Brief: Pharnext Closes 15 Million Euros Financing From CB Lux
Brief: Pharnext Announces Publication Of Preclinical Results For Its PLEODRUG (TM) PXT 3003 In PLOS ONE